Inhibition of lymphangiogenesis of endothelial progenitor cells with VEGFR-3 siRNA delivered with PEI-alginate nanoparticles

International Journal of Biological Sciences

Volumn 10, Issue 2, 2014, Pages 160-170

  Li, Ting ^a   Wang, Guo Dong ^a   Tan, Yu Zhen ^a   Wang, Hai Jie ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Alginate; Endothelial progenitor cells; Nanoparticles; Polyethyleneimine; VEGFR 3

Indexed keywords

ALGINIC ACID; CD34 ANTIGEN; GLUCURONIC ACID; HEXURONIC ACID; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 3;

ALGINATE.; ARTICLE; CELL DIFFERENTIATION; CELL MOTION; CYTOLOGY; DRUG ANTAGONISM; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FETUS BLOOD; GENETICS; HUMAN; LYMPHANGIOGENESIS; METABOLISM; RNA INTERFERENCE; SCANNING ELECTRON MICROSCOPY; STEM CELL; ULTRASTRUCTURE; VEGFR-3;

ALGINATE.; ENDOTHELIAL PROGENITOR CELLS; NANOPARTICLES; POLYETHYLENEIMINE; VEGFR-3;

ALGINATES; ANTIGENS, CD34; CELL DIFFERENTIATION; CELL MOVEMENT; ENDOTHELIAL CELLS; FETAL BLOOD; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; LYMPHANGIOGENESIS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84892742781     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.6719     Document Type: Article

References (44)

1. Detry B, Bruyere F, Erpicum C, et al. Digging deeper into lymphatic vessel formation in vitro and in vivo. BMC Cell Biology. 2011; 12: 29.
2. Tan Y. Basic fibroblast growth factor-mediated lymphangiogenesis of lymphatic endothelial cells isolated from dog thoracic ducts: effects of heparin. Jap J Physiol. 1998; 42: 133-41.
3. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev. 2002; 82: 673-700.
4. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008; 8: 604-17.
5. Paupert J, Sounni NE, Noël A. Lymphangiogenesis in post-natal tissue remodeling: lymphatic endothelial cell connection with its environment. Mol Aspects Med. 2011; 32: 146-58.
6. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011; 17: 1371-80.
7. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol. 2011; 193: 607-18.
8. Al-Rawi MAA, Jiang WG. Lymphangiogenesis and cancer metastasis. Front Biosci. 2011; 16: 723-39.
9. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999; 98: 769-78.
10. Kreuger J, Nilsson I, Kerjaschki D, et al. Early lymph vessel development from embryonic stem cells. Arterioscler Thromb Vasc Biol. 2006; 26: 1073-8.
11. Salven P, Mustjoki S, Alitalo R, et al. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood. 2003; 101: 168-72.
12. Bogos K, Renyi-Vamos F, Dobos J, et al. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res. 2009; 15: 1741-6.
13. Nguyen VA, Furhapter C, Obexer P, et al. Endothelial cells from cord blood CD133+CD34+ progenitors share phenotypic, functional and gene expression profile similarities with lymphatics. J Cell Mol Med. 2009; 13: 522-34.
14. Religa P, Cao R, Bjorndahl M, et al. Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood. 2005; 106: 4184-90.
15. Kerjaschki D, Huttary N, Raab I, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006; 12: 230-4.
16. Schniedermann J, Rennecke M, Buttler K, et al. Mouse lung contains endothelial progenitors with high capacity to form blood and lymphatic vessels. BMC Cell Biol. 2010; 11: 50.
17. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007; 8: 173-84.
18. Pecot CV, Calin GA, Coleman RL, et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011; 11: 59-67.
19. Beloor J, Choi CS, Nam HY, et al. Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials. 2012; 33: 1640-50.
20. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004; 32: e149.
21. Wang HJ, Zhang D, Tan YZ, et al. Autophagy in endothelial progenitor cells is cytoprotective in hypoxic conditions. Am J Physiol Cell Physiol. 2013; 304: C617-26.
22. Wu JH, Wang HJ, Tan YZ, et al. Characterization of rat very small embryonic-like stem cells and cardiac repair after cell transplantation for myocardial infarction. Stem Cells Dev. 2012; 21: 1367-79.
23. Wang HJ, Tan YZ, Zhang MH, et al. Vascular endothelial growth factor-C-induced differentiation of CD34+CD133+VEGFR-3+ EPCs towards lymphatic endothelial cells. Jpn J Lymphology. 2005; 28: 71-3.
24. Patnaik S, Arif M, Pathak A, et al. PEI-alginate nanocomposites: efficient non-viral vectors for nucleic acids. Int J Pharmaceut. 2010; 385: 194-202.
25. Zhang DY, Wang HJ, Tan YZ. Wnt/β-catenin signaling induces the aging of mesenchymal stem cells through the DNA damage response and the p53/p21 pathway. PLoS ONE. 2011; 6: e21397.
26. Guo HD, Wang HJ, Tan YZ, et al. Transplantation of marrow-derived cardiac stem cells carried in fibrin improves cardiac function after myocardial infarction. Tissue Eng Part A. 2011; 17: 45-58.
27. Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990; 96: 121-9.
28. Norrmén C, Tammela T, Petrova TV, et al. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011; 123: 1335-51.
29. Chen Z, Varney ML, Backora MW, et al. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 2005; 65: 9004-11.
30. Lin W, Jiang L, Chen Y, et al. Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer. Cancer Lett. 2012; 314: 127-36.
31. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA. 1995; 92: 3566-70.
32. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005; 97: 14-21.
33. Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006; 66: 2650-7.
34. Burton JB, Priceman SJ, Sung JL, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008; 68: 7828-37.
35. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005; 65: 6901-9.
36. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002; 94: 819-25.
37. Yang H, Kim C, Kim MJ, et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer. 2011; 10: 36.
38. Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res. 2003; 9: 2701-10.
39. Goldsmith M, Mizrahy S, Peer D. Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine. 2011; 6: 1771-85.
40. Akinc A, Thomas M, Klibanov AM, et al. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005; 7: 657-63.
41. Moghimi SM, Symonds P, Murray JC, et al. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/ therapy. Mol Ther. 2005; 11: 990-5.
42. Padmanabhan K, Smith TJ. A preliminary investigation of modified alginates as a matrix for gene transfection in a HeLa cell model. Pharm Dev Technol. 2002; 7: 97-101.
43. Higashi T, Nagamori E, Sone T, et al. A novel transfection method for mammalian cells using calcium alginate microbeads. J Biosci Bioeng. 2004; 97: 191-5.
44. Günther M, Lipka J, Malek A, et al. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm. 2011; 77: 438-49.